HomeCompareCKOCF vs ABBV

CKOCF vs ABBV: Dividend Comparison 2026

CKOCF yields 3.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $75.4K in total portfolio value
10 years
CKOCF
CKOCF
● Live price
3.08%
Share price
$27.11
Annual div
$0.83
5Y div CAGR
7.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$856.48
Full CKOCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CKOCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKOCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKOCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKOCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKOCF
Annual income on $10K today (after 15% tax)
$261.59/yr
After 10yr DRIP, annual income (after tax)
$728.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,328.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKOCF + ABBV for your $10,000?

CKOCF: 50%ABBV: 50%
100% ABBV50/50100% CKOCF
Portfolio after 10yr
$64.6K
Annual income
$12,814.12/yr
Blended yield
19.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CKOCF
No analyst data
Altman Z
4.6
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKOCF buys
0
ABBV buys
0
No recent congressional trades found for CKOCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKOCFABBV
Forward yield3.08%3.06%
Annual dividend / share$0.83$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7.7%40.6%
Portfolio after 10y$26.9K$102.3K
Annual income after 10y$856.48$24,771.77
Total dividends collected$5.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CKOCF vs ABBV ($10,000, DRIP)

YearCKOCF PortfolioCKOCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,031$331.45$11,550$430.00$519.00ABBV
2$12,172$368.03$13,472$627.96$1.3KABBV
3$13,432$408.73$15,906$926.08$2.5KABBV
4$14,827$454.01$19,071$1,382.55$4.2KABBV
5$16,369$504.42$23,302$2,095.81$6.9KABBV
6$18,075$560.53$29,150$3,237.93$11.1KABBV
7$19,964$623.01$37,536$5,121.41$17.6KABBV
8$22,054$692.60$50,079$8,338.38$28.0KABBV
9$24,368$770.12$69,753$14,065.80$45.4KABBV
10$26,930$856.48$102,337$24,771.77$75.4KABBV

CKOCF vs ABBV: Complete Analysis 2026

CKOCFStock

Chudenko Corporation operates as an equipment engineering company in Japan. It undertakes electrical works, such as light/outlet, image/sound/TV/broadcast, power receiving/transforming, and plant equipment works; energy-related works comprising wind/solar power generation, cogeneration, energy-saving power, and private power generation system works; and environment-related works, including recycling and heat storage system works. The company also undertakes electric line/distribution line/leading wire/underground line works; and office/household water and sewerage, and industrial water and sewerage facilities works, as well as constructs, maintains, and repairs roads and architecture. In addition, it is involved in the Internet/Intranet, CATV/community wireless system/telephone, LAN, optical and mobile communication, and OA floor equipment, as well as system integration and integrated information wiring works; air-conditioning/cooling, heating/water supply, drainage/sanitation/environment equipment, and clean room system works; and fire-alarm, theft monitoring/alarm, and firefighting/evacuation guidance equipment works. Further, the company engages in building equipment renewal and housing renovation works, as well as pylon works; designs, produces, sells, repairs, installs, and maintains electrical equipment, such as distribution boards, supervisory panels, control boards, power source equipment, communication devices, heavy current devices, various measuring devices, and others; and plans, develops, sells, rents, operates, and maintains software and information processing systems. Additionally, it provides consulting and maintenance services consisting of energy saving diagnosis/support services, as well as disaster prevention and firefighting equipment inspection services. The company was founded in 1944 and is headquartered in Hiroshima, Japan.

Full CKOCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CKOCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKOCF vs SCHDCKOCF vs JEPICKOCF vs OCKOCF vs KOCKOCF vs MAINCKOCF vs JNJCKOCF vs MRKCKOCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.